The Pharma Data

AUGUST 6, 2020

We pointed out last week that China was a notable missing element in AstraZeneca’s COVID-19 vaccine strategy, despite being the drugmaker’s second-largest market. The pair will also explore the possibility of producing the vaccine for other markets. The vaccine was moved into phase 2/3 in May. That has changed.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52

Eye on FDA

NOVEMBER 17, 2020

Coincident to COVID-19 case levels in Europe and the United States entering new and serious levels comes welcome news on the development of a vaccine. While vaccination may actually begin in December, the number of doses will be limited. In addition, the process of vaccination takes time.

Vaccine 81

Vaccine FDA Hospitals International 81

The Pharma Data

NOVEMBER 17, 2020

Gavi, the Vaccine Alliance welcomes latest pledges in support of the Gavi COVAX AMC , a financing mechanism that will support 92 low- and middle-income economies’ access to safe and effective COVID-19 vaccines. Nine candidate vaccines are currently being supported by CEPI; eight of which are currently in clinical trials.

Vaccine 52

Vaccine Government Clinical Trials Trials 52

The Pharma Data

JANUARY 20, 2021

based Gritstone Oncology is developing a novel COVID-19 vaccine based on adenovirus and messenger-RNA technology designed to combat future variants of the coronavirus. Emeryville, Calif.-based

Vaccine 52

Vaccine RNA Trials Research 52

The Pharma Data

JANUARY 9, 2021

9, 2021 — A task force of allergists and immunologists recommends those administering the COVID-19 vaccine ask patients some key questions beforehand. If the answer is yes, the individual should be referred to a board-certified allergist for evaluation before getting the COVID-19 vaccination, ACAAI said in a news release.

Vaccine 52

Vaccine Immune Response Doctors Disease 52

The Pharma Data

JANUARY 13, 2021

Brazil’s Butantan Institute has reported that Sinovac’s COVID-19 vaccine, CoronaVac, demonstrated an overall efficacy of only 50.38 The researchers previously said that the vaccine offered 78 percent efficacy against mild-to-severe infections, but they failed to include data from volunteers who contracted mild cases.

Vaccine 52

Vaccine Trials Regulations Research 52

The Pharma Data

JANUARY 7, 2021

7, 2021 — The National Football League is asking teams to use their stadiums as places people can go to get vaccinated for COVID-19, CBS News reported Wednesday. ” Using arenas for vaccinations is not a new idea. . ” Using arenas for vaccinations is not a new idea. © 2021 HealthDay.

Vaccine 52

Vaccine 52

The Pharma Data

JANUARY 29, 2021

EU Regulator Approves Oxford-AstraZeneca COVID-19 Vaccine. 29, 2021 — European Union regulators have authorized the AstraZeneca COVID-19 vaccine for use in adults, CBS News reported Friday. The move comes after the European Medicines Agency has been criticized for not moving fast enough to vaccinate its population.

Vaccine 52

Vaccine Regulations Clinical Trials Hospitals 52

The Pharma Data

MAY 4, 2021

Posted 04 May 2021 | By Kari Oakes . The European Medicines Agency (EMA) has added Sinovac’s COVID-19 vaccine to its portfolio of vaccines under rolling review. . CureVac’s CVnCoV COVID-19 vaccine and NVX-CoV2372, the Novavax candidate, have been under review since February 2021. EMA. . . . . .

Vaccine 52

Vaccine RNA Clinical Trials Marketing 52

The Pharma Data

JANUARY 25, 2021

Anaphylaxis Cases Reported Per Million COVID-19 Moderna Vaccine Shots. 25, 2021 — The rate of anaphylaxis is 2.5 cases per million Moderna COVID-19 vaccine doses administered as of Jan. 10, 2021, according to research published in the Jan. anaphylaxis cases per million Moderna COVID-19 vaccine doses administered).

Vaccine 52

Vaccine Research Disease 52

The Pharma Data

AUGUST 13, 2020

The UK government has signed deals for a further 90 million doses of coronavirus vaccine. The vaccines are being developed by the Belgian pharmaceutical company Janssen and the US biotech company Novavax. It means the UK has placed orders for six experimental vaccines, taking its potential stockpile to 340 million doses.

Vaccine 52

Vaccine Virus Government Clinical Trials 52

The Pharma Data

JANUARY 11, 2021

11, 2021 — As the rollout of the COVID-19 vaccines continues, scores of questions are emerging. How do the COVID-19 vaccines work? The COVID-19 vaccines work by teaching the immune system to protect against the virus, experts said. ” Can the vaccines make you sick? MONDAY, Jan.

Vaccine 52

Vaccine Virus DNA Doctors 52

The Pharma Data

JANUARY 4, 2021

4, 2021 — If a second dose of the first COVID-19 vaccine is not available or the maker is not known, then another vaccine may be used, new British guidelines say, The New York Times reported Sunday. Britain has green-lighted vaccines from Pfizer and AstraZeneca. © 2021 HealthDay. Posted: January 2021.

Vaccine 52

Vaccine Virus Production Science 52

The Pharma Data

SEPTEMBER 25, 2020

A trial of a new vaccine that appears to train the immune system to fight coronavirus has begun in the UK. The trial on 10,000 people will now see if the vaccine can prevent people getting ill. A vaccine that can protect people from Covid-19 is still widely seen as the main exit strategy from the restrictions on all our lives.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

JANUARY 8, 2021

Moderna COVID-19 Vaccine Protection May Last Years, Company Claims. 8, 2021 — Moderna CEO Stéphane Bancel said the company’s COVID-19 vaccine may prevent infection for years, CBS News reported Thursday. © 2021 HealthDay. Posted: January 2021. Professional. FRIDAY, Jan. CBS News Article.

Vaccine 52

Vaccine Virus Disease 52

The Pharma Data

JANUARY 20, 2021

Either Trivalent Flu Vaccine Safe for Use in Seniors. 20, 2021 — Either the trivalent adjuvanted inactivated influenza vaccine (aIIV3) or the trivalent high-dose inactivated influenza vaccine (HD-IIV3) is safe to use in older adults, according to a study published online Jan. © 2021 HealthDay. Professional.

Vaccine 52

Vaccine Pharmaceuticals Research 52

The Pharma Data

JANUARY 11, 2021

Two Billion COVID-19 Vaccine Doses From BioNTech Expected This Year. 11, 2021 — A boost in manufacturing should enable Germany’s BioNTech to produce 2 billion doses of its COVID-19 vaccine this year, the company says. BioNTech and partner Pfizer developed the first COVID-19 vaccination to be brought to market.

Vaccine 52

Vaccine Trials Marketing 52

The Pharma Data

NOVEMBER 23, 2020

As the Pfizer-BioNTech COVID-19 vaccine is being evaluated by the U.S. Food and Drug Administration (FDA) and the Moderna vaccine is soon to follow, here’s a look at several of the top COVID-19 vaccine candidates and where they stand as of today. The prices for the vaccines are moving targets, dependent upon the amount ordered.

Vaccine 52

Vaccine Virus Immune Response Trials 52

The Pharma Data

JANUARY 8, 2021

8, 2021 — The COVID-19 vaccine rollout is meeting resistance as many health care workers are refusing shots, the Associated Press reported Friday. a cardiothoracic surgeon in Portland, Oregon, who is postponing getting vaccinated, told the AP. © 2021 HealthDay. Posted: January 2021. FRIDAY, Jan.

Vaccine 52

Vaccine Nurses Hospitals Science 52

The Pharma Data

JANUARY 8, 2021

8, 2021 — As Americans await their COVID-19 shot, a new study of a different vaccine shows the power of Facebook posts in fueling “anti-vax” resistance to immunization. The study included more than 10 years of public Facebook posts on the human papillomavirus (HPV) vaccine. 8 in the journal Vaccine.

Vaccine 52

Vaccine Doctors Virus Disease 52

The Pharma Data

JULY 8, 2021

People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of eight sites, including Salt Lake City. Those who unfortunately got COVID-19 despite being vaccinated were still better off than those who didn’t.”

Vaccine 52

Vaccine Virus Nurses Hospitals 52

The Pharma Data

JANUARY 6, 2021

Two-Thirds of Lupus Patients Likely to Take COVID-19 Vaccine. 6, 2021 — Two-thirds of people with lupus are willing to receive a COVID-19 vaccine, according to the results of a survey released by the Lupus Research Alliance. © 2021 HealthDay. Posted: January 2021. Professional. WEDNESDAY, Jan. 19 and Nov.

Vaccine 52

Vaccine Research 52

The Pharma Data

SEPTEMBER 2, 2020

. Sanofi and GSK have begun a Phase I/II clinical trial testing their adjuvanted COVID-19 vaccine in healthy adults. The vaccine candidate, developed in partnership by the firms, is based on the recombinant protein-based technology used in Sanofi’s seasonal influenza vaccines and GSK’s pandemic adjuvant technology.

Vaccine 52

Vaccine Trials Immune Response Clinical Trials 52

The Pharma Data

MAY 3, 2021

Posted 03 May 2021 | By Kari Oakes . The European Medicines Agency (EMA) is evaluating an application submitted by Pfizer and BioNTech for use of their COVID-19 vaccine in children aged 12 to 15 years. . The vaccine has been authorized by the EU for use in people 16 years and up since December 2020. . EMA. . . .

Vaccine 52

Vaccine RNA Clinical Trials Packaging 52

The Pharma Data

SEPTEMBER 5, 2021

AstraZeneca and the European Commission have reached an agreement that ends legal proceedings over the execution of the Advance Purchase Agreement for the delivery of the COVID-19 vaccine Vaxzevria (ChAdOx1-S [Recombinant]). Legal proceedings by the European Commission against AstraZeneca were initiated in Brussels on 21 April 2021.

Vaccine 52

Vaccine Virus Clinical Trials Trials 52

The Pharma Data

JANUARY 6, 2021

Adults Willing to Take COVID-19 Vaccine Down. 6, 2021 — From April to December, there was a significant decline in the number of Americans who say they are willing to get a COVID-19 vaccine, according to a research letter published online Dec. © 2021 HealthDay. Posted: January 2021. Professional. 25 to Dec.

Vaccine 52

Vaccine Disease Research 52

The Pharma Data

JANUARY 13, 2021

COV2-S Vaccine Seems Safe, Immunogenic for SARS-CoV-2. 13, 2021 — A candidate vaccine, Ad26.COV2.S, 13, 2021 — A candidate vaccine, Ad26.COV2.S, “Our interim analysis indicates that vaccine candidate Ad26.COV2.S “Our interim analysis indicates that vaccine candidate Ad26.COV2.S

Vaccine 52

Vaccine Virus Trials Research 52

The Pharma Data

NOVEMBER 17, 2021

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the last 11 months. 2) From the body of evidence in clinical trials and real-world data, the vaccine has been shown to have an acceptable safety profile.(3,4,5,6,7).

Vaccine 52

Vaccine Clinical Trials Virus Licensing 52

The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Germany and Spain, researchers evaluated blood samples from 322 participants 28-90 days after their last COVID-19 vaccine dose. Using data from the MS PATHS network in the U.S.,

Vaccine 52

Vaccine Therapies Immune Response Disease 52

The Pharma Data

JANUARY 5, 2021

Top FDA Officials Say Two Full Doses of COVID-19 Vaccines a Must. 5, 2021 — Two top officials at the U.S. Food and Drug Administration said Monday that any American who gets the Moderna or Pfizer COVID-19 vaccines must get two full doses, despite international debate on possible ways to stretch vaccine supply.

Vaccine 52

Vaccine FDA Clinical Trials International 52

The Pharma Data

JANUARY 7, 2021

Anaphylaxis Cases/Million Doses of Pfizer-BioNTech COVID-19 Vaccine Reported. 7, 2021 — As of Dec. per million doses administered) after receipt of the first dose of the Pfizer-BioNTech COVID-19 vaccine in the United States, according to research published in the Jan. © 2021 HealthDay. Posted: January 2021.

Vaccine 52

Vaccine Research Disease Drugs 52

The Pharma Data

JANUARY 25, 2021

25, 2021 — Giving melanoma patients a “personalized” vaccine can prompt an anti-tumor immune response that lasts for years, an early study finds. So researchers gave them an experimental vaccine called NeoVax. Unlike traditional vaccines, it is not a one-size-fits-all jab. MONDAY, Jan.

Vaccine 52

Vaccine Immune Response Medical Schools Clinical Trials 52

The Pharma Data

JANUARY 25, 2021

to Get Fewer Vials of Pfizer COVID-19 Vaccine. 25, 2021 — Pfizer will provide fewer vials of its COVID-19 vaccine to the United States in the coming months after it was discovered that it had previously shipped extra doses. © 2021 HealthDay. Posted: January 2021. Professional. MONDAY, Jan. In December, U.S.

Vaccine 52

Vaccine Pharmacy Drugs 52

The Pharma Data

APRIL 20, 2022

Results of a new multicenter study published in the New England Journal of Medicine found that vaccination with a primary series of the Pfizer-BioNTech mRNA COVID-19 vaccine reduced the risk of COVID-19-associated hospitalizations in children ages 5-11 years by two-thirds during the Omicron period.

Vaccine 52

Vaccine Hospitals Research Disease 52

The Pharma Data

JANUARY 21, 2021

21, 2021 — Despite scattered media reports of severe allergic reactions to the Pfizer COVID-19 vaccine, a detailed analysis shows that such incidents are very rare, striking just 11 people for every million doses given. Tom Shimabukuro tracked data on reactions to the Pfizer vaccine soon after it was approved in December.

Vaccine 52

Vaccine Hospitals Disease Research 52

The Pharma Data

DECEMBER 12, 2020

Sanofi and GlaxoSmithKline (GSK) have decided to push back the phase 2b trial of their adjuvanted COVID-19 vaccine after finding it produced only a weak immune response in older patients, delaying the potential delivery of a vaccine that could contribute to the mass vaccination effort in the U.S. to vaccinate on demand.

Vaccine 52

Vaccine Immune Response Trials Research 52

The Pharma Data

MAY 5, 2022

The Fact Sheet for Healthcare Providers Administering Vaccine now reflects the revision of the authorized use of the Janssen COVID-19 Vaccine and includes a warning statement at the beginning of the fact sheet for prominence which summarizes information on the risk for TTS.

Vaccine 52

Vaccine FDA Pharmaceutical Companies Production 52